New York, NY: The long-term use of a proprietary, plant-derived CBD extract is associated with sustained symptom relief in patients with Dravet syndrome (DS) — a refractory form of pediatric epilepsy, according to clinical trial data published in the journal Epilepsia.
An international team of investigators from the United States, the United Kingdom, and Poland assessed the safety and efficacy of the adjunctive use of a purified cannabidiol in a cohort of patients with DS over a period of 48 weeks.
They concluded: "In this open-label extension trial, long-term add-on CBD treatment had an acceptable safety profile in patients with treatment-resistant DS. Reductions in convulsive and total seizure frequency observed in the original placebo-controlled trial were maintained with continued CBD treatment up to 58 weeks, with more than 80 percent of patients/care-givers reporting an improvement in overall condition. Our interim analysis supports the use of add-on CBD as a long-term treatment in patients with DS."
The results were more favorable than those associated with a separate four-year trial assessing the use of purified CBD in patients with either DS or Lennox-Gastaut syndrome. In that trial, CBD was effective long-term in only 27 percent of participants and adverse events were reported in 81 percent of subjects.
In July, the US Food and Drug Administration approved the prescription use of Epidiolex in patients with Lennox-Gastaut syndrome and Dravet syndrome.
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, "Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial," appears in Epilepsia.